Clinical trials: HPV DNA
Papillomavirus Infections
Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)
This study investigates the immunogenicity and safety of the 9vHPV vaccine in healthy Chinese females 9 to 45 years of age. The study consists of Stage I (Day 1 to Month 7) and Stage II (post Month 7 to Month 60).
- Trial name
- NCT03903562
- Testing
- V503
- Where
- 2 sites in China
- Volunteers
- 1,990 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Papillomavirus Infections, Uterine Cervical Neoplasms
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
This study will evaluate the safety and immunogenicity of V503 (GARDASIL™9, 9vHPV vaccine) administered to 9- to 26-year-old females and males in Vietnam.
- Conditions
- Papillomavirus Infections, Uterine Cervical Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms
- Trial name
- NCT03546842
- Testing
- 9vHPV vaccine
- Where
- Vietnam
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV VACCINATION
Health Belief Model-based Education and Motivational Interview Regarding the HPV Vaccination Decision
This research is a single-blind, randomized, parallel-controlled experimental study designed to determine the effect of Health Belief Model (SIM)-based motivational interviews given to mothers of high school students on mothers'…
- Trial name
- NCT04992741
- Testing
- education and motivational interview
- Where
- Turkey (Türkiye)
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Yasemin ATEŞEYAN
Common Wart
A Phase2 of A-101 Topical Solution in Subjects With Common Warts
The primary objective of this study is to evaluate the effectiveness of A-101 compared to vehicle when applied to 1 common target wart on the trunk or extremities.
- Trial name
- NCT03210337
- Testing
- A-101 Topical Solution, A-101 Vehicle Solution
- Where
- 17 sites in United States
- Volunteers
- 157 people
- Sponsor
- Aclaris Therapeutics, Inc.
Cancer of Cervix, HPV Infection
The Effect of Education Given to Women on Cervical Cancer on Knowledge, Attitude and Belief
Aim: The aim of this study is to reveal the effect of education given to women about cervical cancer on knowledge, attitude and belief.
- Trial name
- EEWCCKAB (NCT05990270)
- Testing
- education
- Where
- Turkey (Türkiye)
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Kahramanmaras Sutcu Imam University
HPV Infection
HPV Prevalence in 16-20 Year Old Males
In Quebec, 18 birth cohorts of girls were vaccinated against HPV (aged 9 to 29 years in 2020). With an observed vaccination coverage of >80% an important herd effect might be expected.
- Trial name
- NCT04297670
- Testing
- Measurement of HPV types prevalence
- Where
- Canada
- Volunteers
- 681 people, healthy volunteers welcome
- Sponsor
- Laval University
Common Wart
A Study of A-101 Topical Solution for the Treatment of Common Warts
Phase 3 Study of A-101 Topical Solution in Subjects with Common Warts
- Trial name
- NCT03691831
- Testing
- Active, Vehicle
- Where
- 24 sites in United States
- Volunteers
- 502 people
- Sponsor
- Aclaris Therapeutics, Inc.
HPV Infections
An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)
To prove that quadrivalent HPV (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine is generally safe and well tolerated in the Chinese population.
- Trial name
- NCT00635830
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus (HPV) Infection, HPV (Human Papillomavirus)-Associated Carcinoma
Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging
This vaccine was jointly developed by Chengdu Institute of Biological Products Co., Ltd. and National Vaccine and Serum Institute, China, is co-sponsoring this clinical trial.
- Trial name
- NCT06632912
- Testing
- 2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha), 3 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
- Where
- 3 sites in China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Infections, Papillomavirus
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects
This study is designed to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine in pre-teen and adolescent female subjects aged 9 - 17 years.
- Trial name
- NCT00996125
- Testing
- CervarixTM, Control
- Where
- China
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV Infections
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)
This study is designed to determine the tolerability and immunogenicity of a 3-dose regimen of Gardasil administered to healthy married females between 16 and 23 years of age, in India.
- Trial name
- NCT00733122
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV Infection
Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years
This study aims to assess the immunogenicity and safety of a sequential 2vhpv to 9vhpv immunization schedule in girls aged 9-14 years
- Trial name
- NCT07281677
- Testing
- bivalent HPV vaccine, 9-valent HPV vaccine
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
Common Warts, Plantar Warts
Salicylic Acid Wart Patch for the Treatment of Common Warts and Plantar Warts
Common and plantar warts are a type of skin lesion caused by infection with the human papilloma virus. The incidence of warts is relatively high, with an estimated few to several per cent of the adult population affected.
- Trial name
- NCT06958237
- Testing
- salicylic acid wart patches
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Langsteiner sp. z o.o.